Sanofi (SNY)
(Delayed Data from NSDQ)
$55.47 USD
-0.07 (-0.13%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $55.48 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$55.47 USD
-0.07 (-0.13%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $55.48 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth C Momentum B VGM
Zacks News
Verastem's (VSTM) Copiktra Gets Orphan Drug Designation
by Zacks Equity Research
Verastem's (VSTM) Copiktra gets orphan drug designation from the FDA for use in the treatment of T-Cell lymphoma.
Walgreens (WBA) Becomes Latest Retailer to Suspend Zantac Sales
by Christopher Vargas
Walgreens (WBA) announced today that they would be suspending the sales of Sanofi's (SNY) heartburn medication Zantac.
Zacks.com featured highlights include: Sanofi, KB Home and NRG Energy
by Zacks Equity Research
Zacks.com featured highlights include: Sanofi, KB Home and NRG Energy
Pfizer's JAK1 Inhibitor Meets All Goals in 2nd Phase III Study
by Zacks Equity Research
Pfizer's (PFE) investigational eczema candidate abrocitinib meets all co-primary and secondary endpoints as a monotherapy in the second pivotal late stage study.
SNY or NVO: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
SNY vs. NVO: Which Stock Is the Better Value Option?
Buy These 3 Stocks With Upgraded Broker Ratings Right Now
by Swayta Shah
After thorough research, brokers decide to rate a particular company's stock. Hence, one can be easily rely on the rating.
Here's Why Sanofi (SNY) is Outperforming Its Industry Of Late
by Zacks Equity Research
Sanofi's (SNY) stock is on an upward trajectory this year. Let us have a look at the reasons for the same.
Here's Why AstraZeneca (AZN) is Outperforming Its Industry
by Zacks Equity Research
AstraZeneca's (AZN) stock is on an upward trajectory this year. Let us have a look at the reasons for the same.
Protalix Completes Enrollment in Third Fabry Disease Study
by Zacks Equity Research
Protalix (PLX) completes enrollment in another phase III study of pegunigalsidase alfa (PRX 102) to treat Fabry disease.
Moving Average Crossover Alert: Sanofi
by Zacks Equity Research
Sanofi (SNY) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Are Investors Undervaluing Sanofi (SNY) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
AstraZeneca Gets CHMP Nod for Forxiga/Onglyza Combo Tablet
by Zacks Equity Research
The CHMP recommends AstraZeneca's (AZN) marketing application for Qtrilmet, a combination of Forxiga and Onglyza plus metformin, for treating patients with type-II diabetes.
Regeneron/Sanofi Gets Positive CHMP Opinion for Dupixent
by Zacks Equity Research
Regeneron (REGN) and Sanofi get positive CHMP recommendation for the label expansion of asthma drug Dupixent in an additional indication.
Sanofi (SNY) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Sanofi (SNY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Trovagene's Onvansertib Shows Response in Phase Ib AML Study
by Zacks Equity Research
Trovagene (TROV) successfully completes a phase Ib study, evaluating onvansertib in combination with standard-of-care in AML patients. The regimen is well tolerated and safe.
CGM Devices Gain Steam, Set New Trend in Diabetes Management
by Urmimala Biswas
The FDA authorization classifies the new type of CGM devices in class II and subjects these to certain criteria called special controls.
Alnylam Focuses on Pipeline Development Amid Competition
by Zacks Equity Research
Alnylam (ALNY) is on track with the development of its pipeline despite stiffening competition.
Alnylam Begins Phase III Study on Onpattro for New Indication
by Zacks Equity Research
Alnylam (ALNY) starts phase III APOLLO-B study on its lead drug Onpattro for treating transthyretin amyloidosis with cardiomyopathy. Shares rise.
Abbott Partners With Sanofi to Upgrade Diabetes Management
by Zacks Equity Research
Abbott (ABT) collaborates with Sanofi to revolutionize diabetes care through technological advancements.
Aimmune's Peanut Allergy Drug Gets FDA Committee's Support
by Zacks Equity Research
Aimmune's (AIMT) peanut allergy drug gets majority of votes from the Advisory Committee of the FDA.
Glaxo's Asthma Drug Nucala Gets FDA Nod for Pediatric Use
by Zacks Equity Research
Glaxo's (GSK) asthma medicine, Nucala gets FDA approval for use in pediatric patient population.
J&J's Ponesimod Superior to Aubagio in Relapsing MS Patients
by Zacks Equity Research
J&J (JNJ) announces superiority of its multiple sclerosis candidate, ponesimod compared to Sanofi's Aubagio in patients with relapsing form of the disease.
Lexicon (LXRX) Settles With Sanofi for $260M, Shares Rally
by Zacks Equity Research
Lexicon Pharmaceuticals (LXRX) settles with Sanofi related to termination of their alliance for development of Zynquista in type I and type II diabetes.
Should Value Investors Buy Sanofi (SNY) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Biotech Stock Roundup: REGN Wins Against AMGN, VRTX to Acquire Semma & More
by Ekta Bagri
Key highlights of the past week include litigation updates, acquisitions, and other regulatory and pipeline updates.